Magnesium picolinate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Magnesium picolinate
• 英文别名: magnesium;pyridine-2-carboxylate
• 化学式: C12H8MgN2O4
• 分子量: 268.51
• InChiKey: DMJHMBZIZMPXEH-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -1.49
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• MAGNESIUM PICOLINATE COMPOSITIONS AND METHODS OF USE
  申请人：JDS Therapeutics, LLC

  公开号：US20180098976A1

  公开（公告）日：2018-04-12

  The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.

  本申请涉及镁吡啶酸盐组合物及其使用方法。本文所披露的方法和组合物特别适用于向哺乳动物提供生物可利用的镁，并治疗或预防镁缺乏症状。
• Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus
  申请人：——

  公开号：US20010031744A1

  公开（公告）日：2001-10-18

  This invention relates to nutrient and therapeutic compositions for treatment and prevention of symptoms and disease conditions associated with microangiopathy and macroangiopathy and to methods using the compositions. In particular, the invention relates to compositions useful in the treatment of diabetic retinopathy and nephropathy, to compositions useful in the treatment of other retinal disorders including macular degeneration and cataracts, to compositions useful in wound healing, to compositions useful for treatment and prevention of neuropathy, to compositions useful for treatment and prevention of cardiovascular disease and to compositions useful for the treatment and prevention of dental and periodontal disorders.

  这项发明涉及用于治疗和预防与微血管病和大血管病相关的症状和疾病状况的营养和治疗组合物，以及使用这些组合物的方法。具体来说，该发明涉及用于治疗糖尿病视网膜病和肾病的组合物，用于治疗其他视网膜疾病包括黄斑变性和白内障的组合物，用于伤口愈合的组合物，用于治疗和预防神经病变的组合物，用于治疗和预防心血管疾病的组合物，以及用于治疗和预防口腔和牙周疾病的组合物。
• HIGH-LOADING, CONTROLLED-RELEASE MAGNESIUM ORAL DOSAGE FORMS AND METHODS FOR MAKING AND USING SAME
  申请人：Pharmalyte Solutions, LLC

  公开号：EP3243507A1

  公开（公告）日：2017-11-15

  Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels.

  所公开的是用于口服镁盐的高负载、控释剂型。例如，口服剂型可包含约 80% 至约 95% 的乳酸镁和一种或多种成分。另一个例子是，口服剂型可以包含至少约 50%的镁盐，并表现出控释溶解曲线。还公开了制作控释剂型的方法，用于向哺乳动物口服治疗有效量的镁盐。还公开了治疗以镁缺乏为特征的疾病的方法和预防或缓解低镁水平的方法。
• Liquid dietary supplement formulation compositions
  申请人：Watermins LLC

  公开号：US10251412B2

  公开（公告）日：2019-04-09

  This invention relates to liquid dietary supplement formulation compositions that provide dietary minerals and additional optional ingredients beneficial for health; methods of design and manufacture of such compositions; and methods to enable convenient oral ingestion of the formulation ingredients, by adding the formulations to drinking water, beverages, foods, or meals. The formulation compositions of this invention generally include water, water-soluble calcium compound(s), water-soluble magnesium compound(s), and additional optional ingredients, wherein the sum of the concentrations of the calcium and magnesium compounds is most preferably 2 molar or more, up to the point of saturation. The formulations of this invention possess inherent resistance to microbial growth. The formulations of this invention and variations thereof can be used as dietary supplements to increase intake of beneficial minerals, to mineralize water, to fortify foods or beverages, and can also be used to prepare a variety of additional liquid formulations by varying the calcium and magnesium compounds, and/or by adding one or more compatible ingredient(s).

  本发明涉及提供有益于健康的膳食矿物质和其他可选成分的液态膳食补充剂配方组合物；设计和制造这种组合物的方法；以及通过将配方添加到饮用水、饮料、食品或膳食中，方便口服配方成分的方法。本发明的配方组合物一般包括水、水溶性钙化合物、水溶性镁化合物和其他可选成分，其中钙和镁化合物的浓度之和最好为 2 摩尔或更高，直至饱和点。本发明的配方具有抗微生物生长的固有特性。本发明的制剂及其变体可用作膳食补充剂，以增加有益矿物质的摄入量，使水矿化，强化食品或饮料，也可通过改变钙镁化合物和/或添加一种或多种兼容成分来制备各种其他液体制剂。
• Appetite suppressant compositions and methods thereof
  申请人：Red Mountain Holdings, LLC

  公开号：US11344556B2

  公开（公告）日：2022-05-31

  In various embodiments an appetite suppressant composition comprises at least one anorectic active ingredient (AAI); at least one of a nutritive substance, a controlled drug delivery agent (CDRA), and a cofactor; and optionally, an excipient. The AIA may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The CDRA may comprise a cellulosic. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

  在各种实施方案中，食欲抑制剂组合物包括至少一种厌食症活性成分（AAI）；营养物质、控制给药剂（CDRA）和辅助因子中的至少一种；以及可选的赋形剂。AIA可包括芬特明、芬地美曲秦、地特丙酮、纳曲酮和安非他酮中的任意一种。CDRA 可包括纤维素。辅助因子可包括铬盐或硒盐。在各种实施方案中，本文中的组合物以口服胶囊剂型提供，用于胃肠道给药 AAI。描述了一种抑制需要者食欲的方法。